https://scholars.lib.ntu.edu.tw/handle/123456789/484101
Title: | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy | Authors: | YU-YUN SHAO Huang C.-C. Lin S.-D. CHIH-HUNG HSU ANN-LII CHENG |
Issue Date: | 2012 | Journal Volume: | 18 | Journal Issue: | 14 | Start page/Pages: | 3992-3997 | Source: | Clinical Cancer Research | Abstract: | Purpose: Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulinlike growth factor (IGF)-1 levels. We evaluated whether IGF-1 levels were associated with the outcomes of patients with advanced HCC treated with systemic antiangiogenic therapy. Experimental Design: The study was based on patients with advanced HCC who were enrolled in two clinical trials evaluating first-line combination antiangiogenic therapy. Serum samples were collected before treatment and four to six weeks after the start of treatment. The levels of IGF-1, IGF-2, and IGF-binding protein-3 (IGFBP3) were analyzed for their associations with treatment outcomes. Results: A total of 83 patients were included in the study. Patients who had high (?the median level) baseline IGF-1 levels had significantly higher disease control rate (DCR) than patients who had low ( |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863940804&doi=10.1158%2f1078-0432.CCR-11-2853&partnerID=40&md5=b4be020f6c5414ebd80aeb933ed970c8 https://scholars.lib.ntu.edu.tw/handle/123456789/484101 |
ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-11-2853 | SDG/Keyword: | bevacizumab; capecitabine; somatomedin B; somatomedin binding protein 3; somatomedin C; sorafenib; UFT; adult; advanced cancer; aged; antiangiogenic therapy; article; blood sampling; cancer control; cancer prognosis; female; human; liver cell carcinoma; major clinical study; male; metronomic drug administration; outcome assessment; overall survival; phase 2 clinical trial (topic); priority journal; progression free survival; protein analysis; protein blood level; survival time; treatment duration; treatment response; Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Tegafur; Treatment Outcome |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.